Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | CHKA | P35790 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050318 | 0.87 | AHCY (0.52) | AHCYLMNAADORA3ADORA1ADORA2A | |
| SCHEMBL21050278 | 0.87 | NT5E (0.38) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL21050236 | 0.83 | AHCY (0.38) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL21050315 | 0.83 | AHCY (0.38) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL21050280 | 0.82 | ADORA3 (0.52) | LMNATP53ADORA3ADORA1ADORA2A | |
| Phosphoric Acid SCHEMBL21050309 | 0.82 | P2RY1 (0.36) | AHCYCHKANT5E | |
| Phosphoric Acid SCHEMBL21050313 | 0.82 | P2RY1 (0.36) | AHCYCHKANT5E | |
| SCHEMBL21100356 | 0.77 | AHCY (0.40) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL21100454 | 0.77 | AHCY (0.38) | AHCYLMNATP53ADORA3ADORA1 | |
| SCHEMBL21050319 | 0.74 | LMNA (0.45) | LMNATP53ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040975-B2 | Carbocyclic nucleoside reverse transcriptase inhibitors | SAMHD1, POLRMT, RNGTT | AHCY 206/4885LMNA 2815/4885TP53 4364/4885 |
| US-20190177326-A1 | CARBOCYCLIC NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | SAMHD1, POLRMT, RNGTT | AHCY 206/4885LMNA 2815/4885TP53 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.